Home » Newsletters » BioWorld Science

BioWorld Science

June 8, 2021

View Archived Issues

First-in-human data for GS-5718 shows drug is safe and well tolerated

SYHX-1901 enters phase I trial in healthy Chinese subjects

Phase I trial evaluates GNC-039 in relapsed/refractory or metastatic solid tumors

Results presented from FIH study of RBN-2397 in patients with advanced solid tumors

Chengdu Baiyu Pharmaceutical divulges NLRP3 inflammasome inhibitors

New ERAP1 inhibitors identified at Grey Wolf Therapeutics

Roche discovers Toll-like receptor 7/8/9 antagonists

Sichuan Haisco Pharmaceutical patents G12C mutant KRAS inhibitors

New N-acetyl-beta-D-glucosaminidase inhibitors identified at Janssen

IGF-1Ec expression increased in advanced papillary thyroid carcinoma

Responses seen with BDB-001 plus pembrolizumab in patients with advanced solid tumors

First subject dosed in phase I study of fibrosis candidate RXC-007

Enrollment begins in phase II study of paxalisib in primary CNS lymphoma

StemVacs-V iPSC amplifies cancer-specific immune response and shows synergy with other therapies

First patient dosed in phase II study of CRS-3123 to treat Clostridioides difficile infection

Selpercatinib shows promising safety and efficacy in RET-altered solid tumors in pediatric patients

FDA lifts clinical hold on studies of LentiGlobin in sickle cell disease and beta-thalassemia

MERS coronavirus study gives insights into zoonotic potential

Brentuximab vedotin meets the primary endpoint in diffuse cutaneous systemic sclerosis study

China's NMPA approves clinical trial application for second indication of CT-120

Preliminary phase I data for ST-266 in glaucoma suspect patients

FDA clears IND for CLN-049 bispecific antibody for relapsed/refractory AML

MediciNova initiates sheep study to develop MN-166 as treatment for chlorine gas-induced lung injury

Iksuda completes financing round to support progression of ADCs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...